Primärt mål uppnått Vid en utökad analys, av de åtta patienter med misstänkt endometrios som deltog ...
Mendus has presented positive survival data for the ADVANCE II trial with its lead asset, vididencel...
This Tuesday, between 15:00-18:00, Egetis Therapeutics hosts a Capital Markets Day.
Redeye endorses this morning’s news that IRLAB has submitted a request for an end-of-phase II meetin...
Acquires Svensk Direktreklam for SEK 350m (fully paid in cash).
Redeye gives an initial comment on the news that Saniona has announced a rights issue of around to S...
Biovica’s right issue secures SEK 100m, and the number of shares will increase from 45.
Imlifidase shows a superior ability reducing donor-specific antibodies (DSAs) in the phase 2 study i...
Vitrolife’s CEO Bronwyn Brophy came across as executive and resourceful during her first CMD at Vitr...
edyoutec AB (”edyoutec” eller ”Bolaget”), tidigare Wicket Gaming, har nu påbörjat transformationen m...
Redeye comments on ADVANCE II’s principal investigator presenting an ADVANCE II survival update at A...
AAC Clyde Space's (AAC’s) Q323 report was encouraging, although it benefited from a large element of...
Gasporox has secured a SEK9.1m order for its VialArch product from MaxCann, with deliveries schedule...
Divestment of Oman… With the divestment of its interest in Block 70 in Oman, Maha has continued its ...
The market sentiment is picking up, and Calliditas is interesting ahead of the critical PDUFA date (...
Intäkterna i Q2 slog marknadens förväntningar marginellt.
Redeye endorses the news that Curasight has appointed a CRO, ABX-CRO, to conduct the upcoming phase ...
Redeye is favorable to the news that Lifeclean has decided to improve its short-term financial posit...
Redeye comments on Enviro’s decision to appoint Fredrik Emilson as the new CEO.
Redeye provides a preview ahead of ES Energy Save’s (ES) Q2 2023/24 report, due on the 19th of Decem...
